Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.

CEO

ISIN

CH0325814116

Listings

0 Comments

Share your thoughts

FAQ

What is Kuros Biosciences stock price today?▼

The current price of KURN.SW is CHF23.04 CHF — it has increased by +3.5% in the past 24 hours. Watch Kuros Biosciences stock price performance more closely on the chart.

What is Kuros Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Kuros Biosciences stocks are traded under the ticker KURN.SW.

Is Kuros Biosciences stock price growing?▼

KURN.SW stock has risen by +0.35% compared to the previous week, the month change is a -15.3% fall, over the last year Kuros Biosciences has showed a +18.27% increase.

When is the next Kuros Biosciences earnings date?▼

Kuros Biosciences is going to release the next earnings report on August 13, 2026.

What is Kuros Biosciences revenue for the last year?▼

Kuros Biosciences revenue for the last year amounts to 151.11M CHF.

What is Kuros Biosciences net income for the last year?▼

KURN.SW net income for the last year is -8.58M CHF.

When did Kuros Biosciences complete a stock split?▼

The last stock split for Kuros Biosciences was on June 23, 2016 with a ratio of 1:100.